Polypharmazie – Was tun?

Bei der gleichzeitigen Verordnung mehrerer Arzneimittel sollte eine vernünftige Balance zwischen Risken und Nutzen gefunden werden [1]. So eindeutig eine inflationäre Polypharmazie problematisch erscheint, so eindeutig ist andererseits aber auch, dass eine Untertherapie vermieden werden muss [2]. Im Folgenden wird gezeigt, wie es gelingen kann, komplexe Situationen der Polypharmazie auf einer rationalen und individuellen Basis zu deeskalieren.

Abstract

Polypharmacia is a frequent challenge in modern medicine due to increasing complexity of both patients’ aspects in an ageing society – multimorbidity – and progress of therapeutic approaches. Although risks are clearly increasing with number of simultaneously prescribed drugs, neither analysis of the polypharmacia-problem solely by number nor focusing on deprescribing strategies by number alone is sufficient. The optimum of an overall risk-benefit ratio in the multimorbidity situation has to be described and put into practice by an individualized approach. Pattern analysis may help this, by identifying both the most vulnerable patients and polypharmacia-pattern with pronounced risk burden. Patient vulnerability depends significantly on functional abilities and prioritizing therapeutic goals in a comprehensive deprescribing process needs to implement stage of life and disease.

Schlüsselwörter

Polypharmazie - Deprescribing - Multimorbidität

Key words

polypharmacia - deprescribing - multimorbidity

Publication History

Article published online:
04 January 2021

• Literatur

• 1 Burkhardt H. Umgang mit Multimorbidität und Multimedikation. Stuttgart: Kohlhammer; 2019
• 2 Aronson JK. In defence of polypharmacy. Br J Clin Pharmacol 2004; 57 (02) 119-120
• 3 Gören JL, Parks JJ, Ghinassi FA. et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008; 34 (10) 571-582
• 4 Masnoon N, Shakib S, Kalisch-Ellett L. et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17 (01) 230
• 5 Payne RA. The epidemiology of polypharmacy. Clin Med (Lond) 2016; 16 (05) 465-469 . doi:10.7861/clinmedicine.16-5-465
• 6 Hanlon JT, Hajjar ER. Isn’t It Time We Stop Counting the Number of Drugs to Define Polypharmacy in This New Era of Deprescribing and What Related Outcomes Should Be Measured?. J Am Med Dir Assoc 2018; 19 (08) 644-645
• 7 Mangin D, Bahat G, Golomb BA. et al. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action. Drugs Aging 2018; 35 (07) 575-587
• 8 Assiri GA, Shebl NA, Mahmoud MA. et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts?. BMJ Open 2018; 8 (05) e019101
• 9 Ulley J, Harrop D, Ali A. et al. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr 2019; 19 (01) 15
• 10 Moßhammer D, Haumann H, Mörike K. et al. Polypharmacy-an Upward Trend with Unpredictable Effects. Dtsch Arztebl Int 2016; 113 (38) 627-633
• 11 Boyd CM, Darer J, Boult C. et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716-724
• 12 Wastesson JW, Cedazo Minguez A, Fastbom J. et al. The composition of polypharmacy: A register-based study of Swedes aged 75 years and older. PLoS One 2018; 13 (03) e0194892
• 13 Calderón-Larrañaga A, Vetrano DL, Onder G. et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization. J Gerontol A Biol Sci Med Sci 2017; 72 (10) 1417-1423
• 14 Stock S, Ihle P, Simic D. et al. Prävalenz von Demenz bei Versicherten mit und ohne deutsche Staatsangehörigkeit. Eine Studie auf Basis von Daten der gesetzlichen Krankenversicherung. Bundesgesundheitsbl 2018;
• 15 Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170: 1648-1654
• 16 Foubert K, Mehuys E, Maesschalck J. et al. Pharmacist-led medication review in community-dwelling older patients using the GheOP3 S-tool: General practitioners’ acceptance and implementation of pharmacists’ recommendations. J Eval Clin Pract 2020; 26 (03) 962-972
• 17 Sergi G, De Rui M, Sarti S. et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?. Drugs Aging 2011; 28 (07) 509-518
• 18 Jokanovic N, Tan EC, Dooley MJ. et al. Why is polypharmacy increasing in aged care facilities? The views of Australian health care professionals. J Eval Clin Pract 2016; 22 (05) 677-682
• 19 Petrovic M, Somers A, Onder G. Optimization of Geriatric Pharmacotherapy: Role of Multifaceted Cooperation in the Hospital Setting. Drugs Aging 2016; 33 (03) 179-188
• 20 Wehling M, Burkhardt H, Kuhn-Thiel A. et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 2016; 45: 262-267